For the development of innovative cell-based liver directed therapies, e.g. liver tissue engineering, the use of stem cells might be very attractive to overcome the limitation of donor liver tissue. Liver specific differentiation of embryonic, fetal or adult stem cells is currently under investigation. Different types of fetal liver (stem) cells during development were identified, and their advantageous growth potential and bipotential differentiation capacity were shown. However, ethical and legal issues have to be addressed before using fetal cells. Use of adult stem cells is clinically established, e.g. transplantation of hematopoietic stem cells. Other bone marrow derived liver stem cells might be mesenchymal stem cells (MSC). However, the transdifferentiation potential is still in question due to the observation of cellular fusion in several in vivo experiments.
JCMM JCMM Development of tissue engineering as a novel experimental approach for the treatment of liver diseases
Alternatives to organ transplantation for the treatment of certain liver diseases are currently under investigation. Whole organ liver, split-liver, and related livingdonor liver transplantation are clinically safe and well established procedures for the treatment of end-stage liver failure. However, donor organ shortage and the need of life-long immunosuppressive treatment are still the major limitations of all these options [1] . Therefore, the development of cell based therapeutic strategies for liver diseases are under ongoing experimental evaluation. Using cells instead of organs in this setting should permit (i) expansion of cells in an in vitro phase, (ii) genetic or immunological manipulation of cells for transplantation, (iii) tissue typing and cryopreservation of cells for transplantation in a cell bank, and (iv) the genetic modification of patients own cells for autologuous transplantation [2, 3] . In recent studies, a tissue engineering approach using isolated hepatocytes for in vitro tissue generation and heterotopic transplantation of liver cells has been established [4] . In this setting, a three dimensional matrix was used as a carrier for cell culture and transplantation of hepatocytes. Use of polymeric matrices permits the three dimensional formation of a neo-tissue and specific stimulation of the cells by special modification of the matrix-surface essential for appropriate differentiation of the cells [5, 6] . In such a setting it was shown that coating the matrices with isolated ECM-molecules or modifying the matrices with matrix-bound releasable growth factors (e.g. FGF) could improve sufficient differentiation of hepatocytes [7, 8] . Additionally, culturing hepatocytes on three dimensional matrices permitted culture in a flow bioreactor system with increased function and survival of the cultured cells [9] . Hepatocytes on three dimensional matrices were easily transplanted into rats within the mesenteric leaves in a safe and reversible surgical procedure [10] . Heterotopic transplantation of hepatocytes on matrices allowed the transplantation of a cell number equivalent to a whole organ [11] . Further studies showed an efficient longterm engraftment of hepatocytes in a heterotopic location as well as a proliferation of the engrafted cells [12] . Heterotopically transplanted cells integrated functionally into the recipient and were metabolically active: in the glucuronyl-transferase deficient Gunn rats and Vitamin-C deficient ODS rats a curative metabolic effect was observed after heterotopic transplantation of healthy hepatoctyes [13, 14] . However, though successfully establishing a model providing a combination of in vitro tissue generation and consecutive transplantation of liver cells, hepatocytes still showed only limited growth during culture period. Therefore, the use of highly proliferative cells could be an attractive alternative for improving these approaches. Up to now the formation of an artificial biliary system still remains a challenge in conventional tissue engineering approaches. Therefore, cells for hepatic tissue engineering should ideally be capable to differentiate at least bipotentially towards hepatocytic and biliary cells. In conclusion, the use of highly proliferative stem cells with a bipotential differentiation capacity towards liver cells or biliary cells would be very attractive for cell based alternative treatment approaches for liver diseases, providing (i) expansion of donor or patients cells for transplantation during in vitro phase, (ii) genetic correction or immunologic modification of clonally growing patient cells, and (iii) formation of a functional liver tissue including a biliary system.
Identification and characterization of fetal liver (stem) cells
Different types of hepatic progenitors were identified during fetal liver development. In fetal mouse livers hepatic progenitors were isolated using fluorescence activated cell sorting (FACS) that exhibited typical features of hepatic stem cells: They showed clonogeneic potential in vitro, and had a bipotential differentiation capacity towards liver or biliary cells [15, 16] . The phenotypic marker expression of these cells (c-kit-, CD49f+, CD29+, CD45-, TER119-) resembled that of more immature stem cells, lacking markers of the hepatocytic cell compartments of the fetal liver [17] . Another cell type identified in fetal rat livers was the "fetal liver epithelial progenitor cell" (FLEC) [18, 19] . Similar cells from the mouse also showed bipotential differentiation and a highly proliferative activity after transplantation into adult livers [20] . The marker expression of these cells showed typical features of immature hepatic cells (CK-19, AFP), however expression of stem cell markers remained unknown. In the past the marker expression of different hepatic cell-compartments has been studied thoroughly in the adult liver. In a recent study, we identified different hepatic cell compartments already present during fetal liver development by immunocytochemical analysis: Co-existing in fetal liver cell isolates we found (i) hepatic cells expressing CK-18, and (ii) hepatic cells simultaneously expressing CK-18 and Thy1 [21] . These cells resembled by their phenotypical marker expression stem cells of the adult liver (Oval cells), which showed typically co-expression of hepatocytic and biliary differentiation markers with markers well known from hematopoitic stem cells. [22] [23] [24] [25] . Oval cells of the adult liver have a bipotential differentiation capacity towards hepatocytes or bile duct epithelial cells [26] ; they are highly proliferative under certain conditions, and are clonogenic [27, 28] . Oval cells are involved in liver regeneration only under certain conditions, e.g. after combined liver damages or after activation by specific liver injury models [29, 30] . Cells co-expressing hematopoietic stem cell marker Thy1 and hepatic lineage marker CK-18 may represent early equivalents to the hepatic oval cell in the adult.
Growth expansion and differentiation of fetal liver cells towards mature hepatocytes
In a previous study, we isolated fetal liver cells by three steps (Fig. 1 ): (i) Collagenase/DNAse digestion and Percoll-purification, (ii) MACS-depletion of OX43/OX44 positive hematopoietic cells, and (iii) separation of Thy1-positive or Thy1-negative cells by MACS using Thy1 mAb [31] . RT-PCR analysis and immunocytochemical staining showed liver specific gene expression in double sorted Thy1-positive cells: In this compartment, we observed a constant CK18-RNA expression, a decreasing albumin-RNA expression, and an increasing of AFP-RNA expression in the late fetal period. Thus, Thy1-positive cells showed patterns of dedifferentiation towards the end of the fetal period, while Thy1-negative cells developed towards mature hepatocytes. After isolation of this cell type, in vitro experiments revealed a stemcell like growth potential of these cells. In a further study we investigated the growth and differentiation potential of isolated Thy1 positive or Thy1 negative cells in-vitro [32] . Thy1 positive cells from early fetal liver showed enormous growth (recovery > 1600 %) which was significantly higher than the growth potential of Thy1 negative cells from early fetal liver. Although the growth of Thy1 positive cells was declining with maturation of the fetal liver, it was significantly higher in comparison to the growth of Thy1 negative cells at all times. Thus, Thy1 positive cells can be extensively expanded invitro. Immunocytochemistry and RT-PCR analysis showed that both Thy1 positive cells and Thy1 negative cells expressed the liver specific genes Cytokeratin 18 (CK18), alpha-feto protein (AFP), and albumin during the culture period [ Fig. 2 A/B] . Additionally, in an ongoing study we found, that highly proliferative fetal cells can be expanded serially by passage [ Fig. 3 ]. The use of hepatic stem cells may become important for the improvement of tissue engineering approaches and cell-based therapeutic strategies for liver diseases. For such approaches hepatic stem cells may provide several advantages over hepatocytes: (i) Stem cells could be easily expanded, e.g. during a culture period, and (ii) transduction of stem cells may result in the expansion of "cured" daughter cells [29] . However, the role of fetal liver stem cells for new therapeutic applications has still to be defined; Besides the safety risks, ethical and legal aspects for the use of undifferentiated cells have to be evaluated with care [33] .
Use of adult liver stem cells for liver regeneration
The existence of liver stem cells in the bone marrow was first demonstrated by Petersen et al., who showed that bone marrow cells transplanted into lethally irradiated mice engrafted in the recipients liver, and differentiated into liver stem cells (Oval cells) or mature liver cells (hepatocytes) [34] . These in vivo results were confirmed by mouse experiments [35] , and in patients who received a bone marrow transplantation or peripheral blood stem cell transplantation for hematological disorders [36] [37] [38] . Furthermore, Lagasse et al. found liver specific gene-expression and function in FACS-sorted mouse hematopoietic stem cells (KTLS-cells: c-kit high , thy1 +/-, lin neg , sca-1 + ) after transplantation into FAH-deficient mice [39] . Recent data in the same animal model indicated that cells observed in the recipients liver after stem cell transplantation bearing donor markers and liver specific markers were rather a product of cell fusion than of a real "transdifferentiation" [40, 41] . However, variable data concerning cellular fusion versus transdifferentiation as the source of liver-like differentiated cells derived from bone marrow were found in other animal models: Engraftment of human albumin producing cells in livers of NOD/SCID recipient mice was observed after xenogeneic transplantation of human hematopoietic or umbilical cord blood stem cells; however, fusion events were not ruled out [42] . In contrast to this, two studies in a similar setting found liver specific differentiation of the transplanted cells occurring without any evidence for cell fusion events after transplantation of human sorted CD34+ or unsorted mononuclear cord blood cells into NOD/SCID mice [43, 44] . 
Differentiation of adult bone marrow derived MSC towards liver progenitor cells
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HGF, and was mediated by the expression of its receptor c-met [45] . The expression of liver specific genes (albumin, cytokeratins) in cultured human CD34-positive hematopoietic stem cells or mononuclear cord blood cells was also demonstrated to be induced by HGF in culture [46, 47] . Furthermore, Schwartz et al. isolated CD45 and Glycophorin A depleted multipotent adult progenitor cells (MAPC) from rat, mouse, or human plastic-adherent bone marrow cells that expressed liver specific markers after 14 days in culture with FGF and HGF, e.g. albumin and CK-18 [48] . From cultures of mature hepatocytes it is known, that important stimuli for an adequate cellular differentiation in vitro are (i) the addition of growth hormones and cytokines to the culture medium [49, 50] , (ii) coating culture dishes with extracellular matrix (ECM) molecules [51, 5] , and (iii) the co-culture with other cell types [52, 53] . In stem cell cultures, Miyazaki et al. showed an induction of the liver specific genes albumin, tryptophan-2,3-dioxygenase and tyrosine aminotransferase of rat bone marrow cells indicating a maturation towards hepatocytes, when cultured in a hepatocyte growth medium supplemented with HGF and epidermal growth factor EGF [54] . Avital et al. demonstrated, that β2m-negative thy1-positive stem cells residing in rat bone marrow expressed the liver marker albumin. In co-cultures of these cells with hepatocytes (separated by a PTFEmembrane) these cells were shown to adopt metabolic activity after 7 days in culture [55] . An important influence of hepatocytes on the differentiation of stem cell enriched bone marrow was 
Fig. 4 Rat mesenchymal stem cells (MSC)
from bone marrow were cocultured with adult hepatocytes for induction of liver specific differentiation. Clonally green-fluorescing protein (GFP) positive MSC were co-cultured with adult rat hepatocytes (Hepatocytes; GFP-negative) in a growth hormone supplemented culture medium and on a fibronectin-matrix. Cells from cocultures were isolated and sorted using fluorescence-activated cell sorting (FACS) to obtain GFP-positive or GFP-negative cells for PCRanalysis from the co-cultures.
also highlighted by Okumoto et al. MACSenriched bone marrow stem cells cultured in the presence of HGF and fetal bovine serum (FBS) alone expressed the markers hepatic nuclear factor 1 (HNF1-α) and CK-8 only after 7 days in culture. In cocultures with hepatocytes seperated by a semipermeable membrane the stem cells additionally expressed the liver specific markers AFP and albumin [56] . This suggested, that co-cultured hepatocytes have a stimulatory effect for the differentiation of stem cells towards liver cells, which was mediated by soluble factors. In a recent study by our group, GFP+ clones of rMSC from passage > 9 were used for the differentiation analysis towards liver cells. For liver specific differentiation, cells were cultured in co-cultures with liver cells. For gene-expression analysis, cells from co-cultures were separated in GFP-positive or GFP-negative cells by Fluorescence activated cell sorting before RT-PCR analysis (Fig. 4) [57]. We found that rMSC possess a differentiation potential towards hepatocytic cells in vitro: Expression of the liver specific genes e.g. albumin and CK-19 was demonstrated in GFP+ cells of the cocultures in vitro (Fig. 5 A-C) . This suggested a further differentiation of rat MSC to mature hepatocytic cells, with a mixed phenotype between hepatic and biliary cells (Fig. 6 ) [58] . For other multipotential stem cell types from bone marrow also a hepatocytic differentiation potential was shown by in vitro data: Sorted hematopoietic stem cells [55, 46] , multipotential adult progenitor cells [48] , or side population cells in the liver derived from bone marrow [59] were found to express liver specific genes, when cultured in the presence of growth factors. Our and other studies provide growing evidence that MSC possessed a differentiation potential towards hepatocytic cells, or at least liver stem like cells [60] [61] [62] . Additionally, we could show that for induction of liver specific gene expression co-culture of hepatocytes played a pivotal role.
Finding the right stem cell candidate
Bone-marrow derived liver stem cells, especially MSC are promising candidates for new cell-based approaches for the treatment of liver diseases [63] : transplantation [64] . Thus, the potential of MSC to differentiate towards functional liver cells should be of high interest for new cell-based therapies.
Development of tissue engineering and regeneration approach for liver diseases
For any clinical application of hepatocyte transplantation, a safe mode of supportive orthotopic cell transplantation into the liver would be desir- bone and urothelial cells [68] [69] [70] . Fibrin gel allows as a two-component in situ setting matrix the minimal invasive application of different cell types of tissues. We could show an efficient engraftment of donor derived hepatocytes and non-parenchymal liver cells in the recipients liver by fibrin-matrix based transplantation recently (Fig. 7) [71] . A week after transplantation, the fibrin clot apparently was degraded. CK-18 positive donor hepatocytes were well engrafted within the parenchyma. The histological data provided evidence, that there is an active integration of the transplanted cells in the recipient liver parenchyma, with a high proportion of non-parenchymal liver cells (Fig. 8) . The fibrin matrix was consecutively resorbed by donor cells within days. We suggest that "injectable liver" using a fibrin matrix as carrier for liver cells represents a safe way for application of a sufficient cell mass orthotopically into a favorable environment. Furthermore, it appears to support engraftment and specific differentiation of viable hepatocytes (Fig. 8) . Thus, the results are encouraging that fibrin glue is a suitable matrix for orthotopic transplantation of hepatocytes and stem cell candidates. This "injectable liver" -approach may represent an improved carrier for cell-based therapeutic approaches for liver diseases.
Conclusion
The use of stem cells for liver directed cell-based therapeutic approaches should be very attractive. However, the mechanism for generation of liver cells by stem cells remains still controversial, and in vivo results showed a very low repopulation of the liver by stem cells. Therefore, the development of appropriate methods of cell transplantation is mandatory in order to improve successful repopulation and tissue engineering approaches for liver therapy by stem cells. Furthermore, studies have to show which stem cells (e.g. adult bone marrow derived, fetal organ derived) are superior to use for the formation of functional liver tissue for tissue / organ repair.
